Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 20:48 ET | Source: Robbins LLP

CYTK Investors Should Contact Robbins LLP Regarding the Upcoming Lead Plaintiff Deadline in the Cytokinetics, Inc. Class Action

Cytokinetic stock fell after revelations it misled investors about aficamten’s FDA approval timeline and failed to disclose risks delaying the NDA process
September 19, 2025 16:04 ET | Source: Robbins LLP

CYTK Investor Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Cytokinetics, Inc.

Robbins LLP is Investigating Allegations that Cytokinetics, Inc. (CYTK) Misled Investors About its New Drug Application Submission